Prevalence, incidence and residual risk of transfusion-transmitted hepatitis C virus and human immunodeficiency virus after the implementation of nucleic acid testing in Italy: A 7-year (2009-2015) survey

Blood Transfusion

Volumn 16, Issue 5, 2018, Pages 422-432

  Velati, Claudio ^a,c   Romanò, Luisa ^b   Piccinini, Vanessa ^c   Marano, Giuseppe ^c   Catalano, Liviana ^c   Pupella, Simonetta ^c   Facco, Giuseppina ^c   Pati, Ilaria ^c   Tosti, Maria Elena ^c   Vaglio, Stefania ^c   Grazzini, Giuliano ^c   Zanetti, Alessandro ^b   Liumbruno, Giancarlo M ^c  

^a Italian Society of Tranfusion Medicine and Immunohaematology (SIMTI)   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

HCV; HIV; Incidence; Prevalence; Transfusional residual risk

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CONTROLLED STUDY; FEMALE; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; ITALY; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID ANALYSIS; POLYMERASE CHAIN REACTION; PREVALENCE; VASCULARIZATION; VIRUS TRANSMISSION; ADOLESCENT; BLOOD; HEPACIVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; NUCLEIC ACID AMPLIFICATION; TRANSMISSION;

VIRUS RNA;

ADOLESCENT; ADULT; AGED; BLOOD DONORS; BLOOD TRANSFUSION; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PREVALENCE; RNA, VIRAL;

EID: 85052990210     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2018.0069-18     Document Type: Article

References (31)

1. Regan FA, Hewitt P, Barbara JA, Contreras M on behalf of the current TTI Study Group. Prospective investigation of transfusion transmitted infection in recipients of over 20,000 units of blood. BMJ 2000; 320: 403-6.
2. Soldan K, Barbara JA, Ramsay ME, Hall AJ. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001. Vox Sang 2003; 84: 274-86.
3. Lackritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995; 333: 1721-5.
4. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ for the Retrovirus Epidemiology Donor Study. The risk of transfusion-transmitted viral infections. N Engl J Med 1996; 334: 1685-90.
5. Korelitz JJ, Busch MP, Kleinman SH, et al. A method for estimating hepatitis B virus incidence rates in volunteer blood donors. Transfusion 1997; 37: 634-40.
6. Glynn SA, Kleinman SH, Wright DJ, Busch M P. International application of the incidence rate/window period model. Transfusion 2002; 42: 966-72.
7. Busch MP, Glynn SA, Stramer SL, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005; 45: 254-64.
8. European Medicine Agency. Guideline on epidemiological data on blood transmissible infections. 25 February 2016 EMA/ CHMP/BWP/548524/2008 rev 1 Committee for Medicinal Products for Human Use (CHMP). Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2016/02/WC500202385.pdf. Accessed on 04/04/2018.
9. Annex 4: Guidelines on estimation of residual risk of HIV, HBV or HCV infections via cellular blood components and plasma. In: WHO Expert Committee on Biological Standardization. Sixty-seventh report. WHO technical report series; no. 1004. World Health Organization; 2017. p. 163-96. Available at: http://www.who.int/biologicals/WHO-TRS-1004-web.pdf. Accessed on 04/04/2018.
10. Gonzalez M, Regine V, Piccinini V, et al. Residual risk of transfusion-transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy. Transfusion 2005; 45: 1670-5.
11. Velati C, Romanò L, Fomiatti L. et al. for the SIMTI Research Group. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey. Transfusion 2008; 48: 2205-13.
12. Società Italiana di Medicina Trasfusionale. [Screening of blood donations with NAT techniques in Italy]. Available at: http://www.simti.it/progetto.aspx?id=4&area=1. Accessed on 28/03/2018. [In Italian].
13. Ministry of Health. [Decree of 2 November, 2015. Provisions relating to the quality and safety requisites for blood and blood components. Official Gazette of the Italian Republic December 28, 2015]. [In Italian].
14. Brambilla DJ, Busch MP, Dodd RY, et al for the National Heart, Lung, and Blood Institute Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). A comparison of methods for estimating the incidence of human immunodeficiency virus infection in repeat blood donors. Transfusion 2017; 57: 823-31.
15. Seed CR, Cheng A, Ismay SL, et al. Virology Subcommittee of the National Donor and Product Safety Committee, Australian Red Cross Blood Service. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion 2002; 42: 1365-72.
16. Soldan K, Davison K, Dow B. Estimates of the frequency of HBV, HCV and HIV infectious donations entering the blood supply in the United Kingdom, 1996 to 2003. Viral safety of blood. Eurosurveillance 2005; 10: 17-9.
17. Zou S, Fang CT, Dodd RY for the ARCNET Research Group and Jerome H. Holland Laboratory for Biomedical Sciences. A method for estimating incidence rate of infectious diseases among first-time blood donors. Transfusion 2008; 48: 1827-32.
18. Lefrère JJ, Dahourouh H, Dokekias AE, et al. Estimate of the residual risk of transfusion-transmitted human immunodeficiency virus infection in sub-Saharan Africa: a multinational collaborative study. Transfusion 2011; 51: 486-92.
19. Zou S, Stramer SL, Dodd RY. Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations. Transf Med Rev 2012; 26: 119-28.
20. O'Brien SF, Yi QL, Fan W, et al. Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services. Vox Sang 2012; 103: 83-6.
21. de Almeida-Neto C, Sabino EC, Liu J, et al. Prevalence of serological markers for hepatitis B and C viruses in Brazilian blood donors, and incidence and residual risk of transfusiontransmission of hepatitis C virus. Transfusion 2013; 53: 827-34.
22. Vieira PC, Lamarão LM, Amaral CE, et al. Residual risk of transmission of human immunodeficiency virus and hepatitis C virus infections by blood transfusion in northern Brazil. Transfusion 2017; 57: 1968-76.
23. th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42: 975-9.
24. Weusten J, Vermeulen M, van Drimmelen H, Lelie N. Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms. Transfusion 2011; 51: 203-15.
25. Suligoi B, Pupella S, Regine V, et al. Changing blood donor screening criteria from permanent deferral for men who have sex with men to individual sexual risk assessment: no evidence of a significant impact on the human immunodeficiency virus epidemic in Italy. Blood Transfus 2013; 11: 441-8.
26. Regine V, Pugliese L, Boros S, et al. [Update of new diagnoses of HIV infection and AIDS cases in Italy at December 31, 2016.] Not Ist Super Sanità 2017; 29 (9 Suppl 1): 3-51. [In Italian].
27. Pillonel J, Laperche S. Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Eurosurveill 2005; 10: 5-8.
28. Custer B, Kessler D, Vahidnia F, et al. Risk factors for retrovirus and hepatitis virus infections in accepted blood donors. Transfusion 2015; 55: 1098-107.
29. Goldman M, O'Brien SF. Donor deferral policies for men who have sex with men: where are we today? Curr Opin Hematol 2016; 23: 568-72.
30. Bes M, Piron M, Casamitjana N, et al. Epidemiological trends of HIV-1 infection in blood donors from Catalonia, Spain (2005-2014). Transfusion 2017; 57: 2164-73.
31. Calman K. Cancer: science and society and the communication of risk. BMJ 1996; 13: 799-802. Arrived: 10 April 2018 - Revision accepted: 4 June 2018